Pulmonary Fibrosis

Patients with IPF hospitalized for CDI had higher mortality, longer stays, and greater costs.

TETON-1 data show inhaled treprostinil improves FVC and reduces worsening in IPF, supporting a potential new treatment and combo strategy.

Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis.

Explore frequently asked questions on IPF therapies, including approved drugs, emerging treatments, and approaches to slow fibrosis.

Deupirfenidone received orphan drug designation from the FDA and European Commission for idiopathic pulmonary fibrosis treatment.

A new study links telomere length genetics to IPF risk, showing how rare variants and polygenic scores may guide future screening and precision care.

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL measures into trials is urgently needed.

Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations.

ACE inhibitors may improve survival in IPF patients, highlighting potential repurposing of a common cardiovascular drug.

A study shows that PF impacts sexual activity physically and emotionally, emphasizing the need for holistic patient care and quality-of-life assessments.

Oral nalbuphine significantly reduced cough frequency and severity in idiopathic pulmonary fibrosis (IPF), with patients seeing greater benefit at higher doses.

Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis biomarkers, supporting disease-modifying potential in IPF.

Mass spectrometry technology identified proteomic biomarkers of IPF, but more work will be needed to fully translate these findings to the clinic.

Traditional Chinese medicine relies on nonlinear, unstructured data, but a new report suggests its practitioners can still benefit from machine learning, including in the treatment of idiopathic pulmonary fibrosis.

A look back at the breakthroughs in pulmonary fibrosis research, including FDA-approved treatments and innovative diagnostic techniques.

The approval was based on the pivotal phase 3 FIBRONEER-ILD trial, in which nerandomilast slowed lung function decline in PPF and had similar discontinuation rates to placebo.

The 2025 American Thoracic Society International Conference brought advancements in pulmonary medicine and highlighted the need for health equity reforms.

Patients with pulmonary fibrosis (PF) obtain much of their information from the internet, a new report finds, even though a significant amount of information on the internet is incomplete or inaccurate.

Discover key insights from the ERS Congress 2025, highlighting advancements in pulmonary fibrosis treatment and the promising role of nerandomilast.

Common and rare genetic variants linked to idiopathic pulmonary fibrosis (IPF) and reveals substantial genetic overlap with severe COVID-19, highlighting shared biological pathways and potential therapeutic targets.

New research shows patients commonly take lower doses of nintedanib, and the majority are also taking immunomodulatory drugs.

Higher CONUT nutritional scores strongly predict poorer survival and greater lung function decline in PPF, highlighting malnutrition as a key modifiable risk factor.

Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis.

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.